Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

The Link Between Diet Quality and CRC Outcomes

November 12, 2018
By Leah Lawrence
Article

A study looks at how dietary patterns impact colorectal cancer outcomes before and after diagnosis.

People who have diets with a higher intake of plants and lower intake of animal products both before and after diagnosis with colorectal cancer survived longer, according to a new study. The results indicate the “importance of diet quality as a potentially modifiable tool to improve prognosis among men and women with colorectal cancer.”

The reduced mortality was seen among participants who had a higher ACS score based on the American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Prevention, which recommends at least five servings per day of fruits and vegetables, a high variety of fruits and vegetables, whole grains over refined grains, and limited red or processed meat.

“The ACS score was the only dietary pattern we evaluated that was derived specifically for cancer prevention, which may explain why its results were more strongly inverse than the other dietary patterns,” Mark A. Guinter, PhD, MPH, of the American Cancer Society, and colleagues wrote in the Journal of Clinical Oncology.

The study is the first of its kind to look at change in dietary quality from pre- to post-diagnosis of colorectal cancer. In the Cancer Prevention Study-II Nutrition Cohort, there was 2,801 participants without cancer in 1992/1993 who were later diagnosed with nonmetastatic colorectal cancer. Pre-diagnosis diet information was available for 2,671 participants and post-diagnosis data for 1,321 participants. The researchers looked at the Dietary Approaches to Stop Hypertension (DASH), ACS-score, prudent, and Western dietary patterns to evaluate diet quality.

Those participants with the highest ACS score prediagnosis had a 22% lower risk for all-cause mortality compared with participants with the lowest ACS score (95% CI, 5%–35%). Inverse trends were found for ACS score and both all-cause mortality and colorectal cancer-specific mortality. Higher Western diet score was associated with higher all-cause mortality compared with those with the lowest Western diet score.

Post-diagnosis, higher scores for DASH, ACS score, and prudent diets were all significantly associated with lower all-cause mortality, leading to 21%, 38%, and 28% lower risk, compared with participants with the lowest scores for those dietary patterns. Reduced colorectal cancer-specific mortality risk was found with higher DASH and ACS-score compared with increased risk with increasing Western diet quartiles.

“Consistently observed inverse associations suggest that prognosis may improve with better post-diagnosis diet, even when prediagnosis diet quality was relatively low,” the researchers wrote. “These results were supported further in postdiagnostic models that identified statistically significant associations between diet quality and mortality that were independent of prediagnosis diet quality.”

Based on these results, the researchers wrote that recommendations should be made in support of high diet quality before and after colorectal cancer diagnosis to improve survival.

“Collectively, the results from all dietary patterns suggest that consumption of a diet high in plant products and fiber while limiting red and processed meat and added sugars both before and after diagnosis may be beneficial,” the researchers wrote.

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

Roman Fabbricatore
July 28th 2025
Article

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.


Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Tim Cortese
July 19th 2025
Article

Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.

Related Content
Advertisement

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.

IDMC Recommends Continuation of ELI-002 7P Trial in PDAC

Roman Fabbricatore
August 5th 2025
Article

The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.

Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer

Roman Fabbricatore
July 28th 2025
Article

Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Radiotherapy Plus Sintilimab and Chemo Improves pCR in Rectal Cancer

Tim Cortese
July 20th 2025
Article

Short-course radiotherapy combined with sintilimab plus oxaliplatin-capecitabine yielded a pCR rate of 59.2% vs 32.7% with the control arm in locally advanced rectal cancer.


Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Tim Cortese
July 19th 2025
Article

Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.